Dendreon Gives Quarterly Report & Provenge Updates (DNDN)

Dendreon Corp. (NASDAQ: DNDN) has its quarterly results out, although it is via SEC Filing rather than via a press release.  We had this on deck for a report this week and a conference call was set for Tuesday at 11:30 AM EST.

Dendreon’s total operating expenses were $20.929 million and net loss after items of $126.7 million after a $105+ million warrant item.  That is not just from operations and it does include many ongoing or new items.  That comes to a loss of $1.20 EPS and revenues were listed as $25,000.00.

More importantly, the company disclosed its expansion facilities and the associated costs in Georgia and in California.  Dendreon is still expecting PROVENGE to be approved and it gave updates along those lines.

FULL DETAILS of the financial data and updates on Provenge are at BioHealthInvestor.com.